Department of Gastroenterology, Hepatology, and Nutrition, Cleveland Clinic, Cleveland, Ohio, USA.
Curr Opin Gastroenterol. 2020 Jul;36(4):310-316. doi: 10.1097/MOG.0000000000000642.
The cost of care for inflammatory bowel disease (IBD) has nearly doubled over the last two decades. With evolving treatment paradigms utilizing costly but efficacious biologic agents earlier and more often, the cost burden is only expected to worsen. The purpose of this review is to explore the current economic landscape and drivers of IBD healthcare costs along with potential mechanisms for improving value and cost-effectiveness of IBD care.
The prevalence of IBD continues to rapidly expand with costs following suit. As compensation models change, the medical community is more incentivized than ever to develop cost reduction strategies including incorporation of high-value care measures, cooperative data aggregation, and technological solutions, with many of these interventions demonstrating promising results.
IBD is an expensive chronic disease with payments only expected to rise. In light of this financial conundrum, new practice models, such as the IBD specialty medical home and remote telemedicine, are being tested with an emphasis on cost reduction. Many of these strategies are demonstrating improved patient outcomes while also curbing expenses. These early successes set the stage for continued cooperation, collaboration, and growth in value-based management of IBD.
过去二十年来，炎症性肠病（IBD）的治疗费用几乎翻了一番。随着更早期和更频繁地使用昂贵但有效的生物制剂来改变治疗模式，成本负担预计只会恶化。本综述的目的是探讨 IBD 医疗保健成本的当前经济状况和驱动因素，以及提高 IBD 护理的价值和成本效益的潜在机制。
IBD 的患病率仍在迅速扩大，其成本也随之增加。随着补偿模式的改变，医学界比以往任何时候都更有动力制定成本降低策略，包括采用高价值护理措施、合作数据汇总和技术解决方案，其中许多干预措施已显示出可喜的结果。
IBD 是一种昂贵的慢性疾病，支付费用预计只会上升。鉴于这一财务难题，IBD 专业医疗之家和远程远程医疗等新的实践模式正在进行测试，重点是降低成本。这些策略中的许多都在改善患者的预后，同时也控制了费用。这些早期的成功为基于价值的 IBD 管理的持续合作、协作和发展奠定了基础。
